327 related articles for article (PubMed ID: 29063514)
1. Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C.
de Almeida SM; Ribeiro CE; Rotta I; Piovesan M; Tang B; Vaida F; Raboni SM; Letendre S; Potter M; Batistela Fernandes MS; Ellis RJ;
J Neurovirol; 2018 Feb; 24(1):28-40. PubMed ID: 29063514
[TBL] [Abstract][Full Text] [Related]
2. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.
Gisslén M; Krut J; Andreasson U; Blennow K; Cinque P; Brew BJ; Spudich S; Hagberg L; Rosengren L; Price RW; Zetterberg H
BMC Neurol; 2009 Dec; 9():63. PubMed ID: 20028512
[TBL] [Abstract][Full Text] [Related]
3. Neprilysin in the Cerebrospinal Fluid and Serum of Patients Infected With HIV1-Subtypes C and B.
de Almeida SM; Tang B; Ribeiro CE; Rotta I; Vaida F; Piovesan M; Batistela Fernandes MS; Letendre S; Potter M; Ellis RJ;
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):248-256. PubMed ID: 29481488
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.
Peterson J; Gisslen M; Zetterberg H; Fuchs D; Shacklett BL; Hagberg L; Yiannoutsos CT; Spudich SS; Price RW
PLoS One; 2014; 9(12):e116081. PubMed ID: 25541953
[TBL] [Abstract][Full Text] [Related]
5. Blood amyloid-β protein isoforms are affected by HIV-1 in a subtype-dependent pattern.
de Almeida SM; Ribeiro CE; Rotta I; Letendre S; Potter M; Tang B; Batistela M; Vaida F; Ellis RJ;
J Neurovirol; 2020 Feb; 26(1):3-13. PubMed ID: 31281948
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections.
Krut JJ; Zetterberg H; Blennow K; Cinque P; Hagberg L; Price RW; Studahl M; Gisslén M
J Neurol; 2013 Feb; 260(2):620-6. PubMed ID: 23052602
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity.
Honig LS; Kang MS; Lee AJ; Reyes-Dumeyer D; Piriz A; Soriano B; Franco Y; Coronado ZD; Recio P; Mejía DR; Medrano M; Lantigua RA; Teich AF; Dage JL; Mayeux R
JAMA Netw Open; 2023 Apr; 6(4):e238214. PubMed ID: 37079306
[TBL] [Abstract][Full Text] [Related]
8. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of fluid biomarkers in Alzheimer's Disease.
Lewczuk P; Łukaszewicz-Zając M; Mroczko P; Kornhuber J
Pharmacol Rep; 2020 Jun; 72(3):528-542. PubMed ID: 32385624
[TBL] [Abstract][Full Text] [Related]
10. Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease.
Brinkmalm G; Brinkmalm A; Bourgeois P; Persson R; Hansson O; Portelius E; Mercken M; Andreasson U; Parent S; Lipari F; Ohrfelt A; Bjerke M; Minthon L; Zetterberg H; Blennow K; Nutu M
Brain Res; 2013 Jun; 1513():117-26. PubMed ID: 23541617
[TBL] [Abstract][Full Text] [Related]
11. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
[TBL] [Abstract][Full Text] [Related]
12. Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers.
Orduña Dolado A; Stomrud E; Ashton NJ; Nilsson J; Quijano-Rubio C; Jethwa A; Brum WS; Brinkmalm Westman A; Zetterberg H; Blennow K; Janelidze S; Hansson O
Alzheimers Res Ther; 2024 Jun; 16(1):132. PubMed ID: 38909218
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease.
Rosén C; Andreasson U; Mattsson N; Marcusson J; Minthon L; Andreasen N; Blennow K; Zetterberg H
Neuromolecular Med; 2012 Mar; 14(1):65-73. PubMed ID: 22350541
[TBL] [Abstract][Full Text] [Related]
14. CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.
Toledo JB; Korff A; Shaw LM; Trojanowski JQ; Zhang J
Acta Neuropathol; 2013 Nov; 126(5):683-97. PubMed ID: 23812319
[TBL] [Abstract][Full Text] [Related]
15. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis.
Luo X; Shi H; Hou L; Zhong X; Chen X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chen J; Fang Y; He H; Ning Y
Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998
[TBL] [Abstract][Full Text] [Related]
16. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus.
Pyykkö OT; Lumela M; Rummukainen J; Nerg O; Seppälä TT; Herukka SK; Koivisto AM; Alafuzoff I; Puli L; Savolainen S; Soininen H; Jääskeläinen JE; Hiltunen M; Zetterberg H; Leinonen V
PLoS One; 2014; 9(3):e91974. PubMed ID: 24638077
[TBL] [Abstract][Full Text] [Related]
18. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
[TBL] [Abstract][Full Text] [Related]
19. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals.
Simrén J; Brum WS; Ashton NJ; Benedet AL; Karikari TK; Kvartsberg H; Sjons E; Lussier FZ; Chamoun M; Stevenson J; Hopewell R; Pallen V; Ye K; Pascoal TA; Zetterberg H; Rosa-Neto P; Blennow K
Alzheimers Res Ther; 2022 Dec; 14(1):192. PubMed ID: 36544221
[TBL] [Abstract][Full Text] [Related]
20. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
